The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC
HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and ...
Heparin, a widely available drug traditionally used to treat blood clots, lowers risk of death and ventilation in patients with COVID-19. The corresponding study was published in eClinical Medicine.
WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks ®, the largest ambulatory cloud EHR, today announced that Blue Bonnet Family Medicine Health and Wellness Clinic (Blue Bonnet) — a Texas-based ...
A machine commonly used for pain relief has shown to improve breathing in patients with obstructive sleep apnea, a clinical trial has found. Results of the TESLA trial, published today in eClinical ...
eClinical solutions, software, and apps allow clinical research and trials to be managed rapidly and effectively. The software programs that are included in the eClinical solutions category assist ...
WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR, announced that York Primary Care is successfully leveraging eClinicalWorks AI-powered EHR technology, including ...
The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC
Ivonescimab is the world's first PD-1/VEGF bispecific antibody for which a New Drug Application (NDA) has been submitted. Based on the published results, the combination of ivonescimab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results